Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.70    0.00 (0.00%)
Bid:
1.70
Ask:
2.16
Spread: 0.46 (27.059%)
Market Cap: £5.96m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

License Agreement

9 Apr 2010 07:00

RNS Number : 9292J
Proteome Sciences PLC
09 April 2010
 



 

 

Proteome Sciences plc

ProteoPrep License agreement with Sigma-Aldrich

 

 

9th April, 2010 Proteome Sciences plc ("Proteome Sciences") is pleased to announce that it has entered into a non-exclusive license agreement with Sigma-Aldrich Corporation ("Sigma") under which Sigma will be able to continue selling products under Proteome's registered trademark ProteoPrep® in Europe, Japan and Australia. Sigma is the world's largest supplier of research biochemicals and organic chemicals with over one million customers.

 

There are currently eleven ProteoPrep® kits available from Sigma and the license will also include all future products sold under the ProteoPrep® trademark that contain chemicals and reagents for the disruption of cells, tissues or other biological material and the extraction of biological molecules like proteins, lipids and carbohydrates. It also covers methods and processes relating to assays for the diagnosis of diseases and chemical markers determining targets for drugs and for determining proteins and peptides by disruption of cells, tissues or other biological material. The license provides Proteome with a signature fee and royalties on all ProteoPrep® sales in the jurisdictions listed above.

 

Commenting on the license Christopher Pearce, Chief Executive of Proteome Sciences said:

 

"We are delighted to have concluded the license with Sigma-Aldrich Corporation for the ProteoPrep® trademark and look forward to receiving this new stream of revenue from royalties generated by their successful and expanding range of ProteoPrep® products."

 

 

 

- End -

 

 

For further information please contact:

 

Proteome Sciences plc

www.proteomics.com Tel: +44 (0)1932 865065

Christopher Pearce, Chief Executive Officer christopher.pearce@proteomics.com 

James Malthouse, Finance Director james.malthouse@proteomics.com 

Dr. Ian Pike, Chief Operating Officer ian.pike@proteomics.com 

 

Nominated Adviser

Singer Capital Markets Limited

Shaun Dobson/Claes Spång

Tel: +44 (0)20 3205 7500

 

Public Relations

IKON Associates Redleaf Communications Limited

Adrian Shaw Anna Dunkin/Lucy Salaman

Tel: +44 (0)1483 535102 Tel: +44 (0)20 7566 6700

Mobile: +44 (0)7979 900733 Email: proteome@redleafpr.com 

Email: adrian@ikonassociates.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRLLFLRSDITIII
Date   Source Headline
30th Jun 20104:27 pmRNSResult of AGM,Loan Conversion,Total Voting Rights
28th Jun 20105:59 pmRNSCOMPLETION OF PLACING AND OVERSUBSCRIBED OPEN OFFE
18th Jun 20107:00 amRNSUpdate on warranty claim
17th Jun 20109:00 amRNSReport and Accounts
11th Jun 20107:00 amRNSPublication of Circular
8th Jun 201011:21 amRNSHolding(s) in Company
7th Jun 20104:40 pmRNSSecond Price Monitoring Extn
7th Jun 20104:35 pmRNSPrice Monitoring Extension
7th Jun 20104:22 pmRNSPreliminary Results
7th Jun 20104:17 pmRNSPlacing, Open Offer & Loan Conversion
2nd Jun 20107:00 amRNSReimbursement of lung cancer test in USA
26th Apr 201011:55 amRNSBlocklisting Interim Review
9th Apr 20107:00 amRNSLicense Agreement
11th Feb 20108:18 amRNSAlliance with Parexel
9th Feb 20107:00 amRNSChange of Adviser
1st Feb 20102:01 pmRNSHolding(s) in Company
23rd Dec 20093:55 pmRNSDirectorate Change
16th Nov 20091:39 pmRNSHolding(s) in Company
28th Oct 20097:00 amRNSRe Contract
26th Oct 20097:00 amRNSBlock Admission
23rd Oct 20094:40 pmRNSSecond Price Monitoring Extn
23rd Oct 20094:35 pmRNSPrice Monitoring Extension
30th Sep 20097:00 amRNSHalf Yearly Report
25th Sep 20094:40 pmRNSSecond Price Monitoring Extn
25th Sep 20094:35 pmRNSPrice Monitoring Extension
10th Sep 20094:40 pmRNSSecond Price Monitoring Extn
10th Sep 20094:35 pmRNSPrice Monitoring Extension
9th Sep 20094:40 pmRNSSecond Price Monitoring Extn
9th Sep 20094:35 pmRNSPrice Monitoring Extension
28th Aug 20094:40 pmRNSSecond Price Monitoring Extn
28th Aug 20094:35 pmRNSPrice Monitoring Extension
16th Jul 20093:39 pmRNSHolding(s) in Company
14th Jul 200910:26 amRNSResult of AGM
6th Jul 20097:00 amRNSLicensing Agreement
30th Jun 20094:40 pmRNSSecond Price Monitoring Extn
30th Jun 20094:35 pmRNSPrice Monitoring Extension
22nd Jun 20098:00 amRNSPosting of Report & Accounts
18th Jun 20097:00 amRNSPreliminary Results
27th May 20097:00 amRNSLicense Agreement in Brain Damage
5th May 20092:40 pmRNSHolding(s) in Company
28th Apr 20092:20 pmRNSBlocklisting Interim Review
30th Mar 20097:00 amRNSChange of Adviser
23rd Mar 200910:30 amRNSHolding(s) in Company
18th Mar 20094:55 pmRNSHolding(s) in Company
9th Mar 20097:00 amPRNISO 9001: 2008 Certification
26th Feb 200911:09 amPRNCorrection : Holding(s) in Company
26th Feb 20099:00 amPRNHolding(s) in Company
15th Jan 20094:41 pmRNSSecond Price Monitoring Extn
15th Jan 20094:35 pmRNSPrice Monitoring Extension
6th Jan 20099:57 amPRNTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.